ALKS

Alkermes plc

Insider Trades

ActorHolding ValueLast TransactionAmountTransaction PriceCurrent Price
Gaffin David JosephEVP, CLO, Alkermes, Inc.
$9.9M229.5k shares
SellJun 4, 2026
$87.6K2k shares
$43.05
--
Hopkinson Craig C.EVP R&D, Chief Medical Officer
$3.2M77.4k shares
SellJun 1, 2026
$375.0K9k shares
$41.67
--
Hopkinson Craig C.EVP R&D, Chief Medical Officer
$123k6.4k shares
Grant / ExerciseJun 1, 2026
$96.7K5k shares
$19.34
--
Parisi Samuel JosephVP, Finance (Interim PAO)
$327k7.7k shares
SellMay 29, 2026
$687.0K16.2k shares
$42.36
--
Parisi Samuel JosephVP, Finance (Interim PAO)
$248k12.8k shares
Grant / ExerciseMay 29, 2026
$248.0K12.8k shares
$19.34
--
Parisi Samuel JosephVP, Finance (Interim PAO)
$68k3.4k shares
Grant / ExerciseMay 29, 2026
$67.9K3.4k shares
$20.03
--

News

marketbeat.comAlkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nearsmarketbeat.comJun 10seekingalpha.comAlkermes plc (ALKS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.comJun 10gurufocus.comAlkermes PLC (ALKS) Shares Surge 4.4% -- What GF Score of 74 Tells Investorsgurufocus.comJun 9fool.comHealthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotechfool.comJun 5zacks.comAlkermes (ALKS) Up 21.1% Since Last Earnings Report: Can It Continue?zacks.comJun 4